Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kite

21.36
+0.32001.52%
Post-market: 21.360.00000.00%16:30 EDT
Volume:2.20M
Turnover:47.16M
Market Cap:4.69B
PE:1.15K
High:21.67
Open:21.16
Low:20.92
Close:21.04
Loading ...

Kite Realty Group Trust - Expects 2025 Net Income of $0.45 to $0.51/Share

THOMSON REUTERS
·
12 Feb

Kite Realty Gr Trust Q4 2024 NAREIT FFO Per Share $0.53, Inline

Benzinga
·
12 Feb

Kite Realty Gr Trust Q4 Sales $214.72M Beat $208.50M Estimate

Benzinga
·
12 Feb

Kite Realty Group Trust Q4 Basic EPS USD 0.1

THOMSON REUTERS
·
12 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
10 Feb

Kite Realty Group Trust expected to post earnings of 10 cents a share - Earnings Preview

Reuters
·
08 Feb

Jefferies Keeps Their Hold Rating on Kite Realty Group (KRG)

TIPRANKS
·
04 Feb

Kite Realty Group Trust Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
30 Jan

Piper Sandler Sticks to Their Buy Rating for Kite Realty Group (KRG)

TIPRANKS
·
27 Jan

Kite Realty Group Trust Is Maintained at Neutral by JP Morgan

Dow Jones
·
15 Jan

Kite Realty Group Trust Shares Fall After Jefferies Downgrade

MT Newswires Live
·
03 Jan

Jefferies Downgrades Kite Realty Group Trust to Hold From Buy, Adjusts Price Target to $27 From $31

MT Newswires Live
·
02 Jan

U.S. RESEARCH ROUNDUP-Biogen, Crown Castle, Eastgroup Properties

Reuters
·
02 Jan

Kite Realty Group Trust : Jefferies Cuts to Hold From Buy

THOMSON REUTERS
·
02 Jan

Kite Realty downgraded to Hold from Buy at Jefferies

TIPRANKS
·
02 Jan

Kyverna Therapeutics Picks Former Atara Bio, Kite Executives for Leadership Roles

MT Newswires Live
·
14 Dec 2024

KITE REALTY GROUP PARTNERS WITH FIFTH WALL

PR Newswire
·
11 Dec 2024

Gilead’s Kite announces results from 5-year follow-up study of Yescarta in NHL

TIPRANKS
·
10 Dec 2024

Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

Business Wire
·
10 Dec 2024

Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Business Wire
·
10 Dec 2024